HOME >> MEDICINE >> NEWS
Alzheimer's pathology reduced, longevity improved in mouse model, Gladstone study shows

Removal of an enzyme that regulates the activity of many proteins can suppress key features of Alzheimer's disease in experimental models, researchers at the Gladstone Institute of Neurological Disease (GIND) recently reported in the Journal of Neuroscience (May 12, 2004).

Using well-established mouse models of Alzheimer's disease, the investigators examined how changing levels of the enzyme Fyn affects key aspects of the disease, including accumulation of large clumps of amyloid proteins in the brain (so-called plaques) and changes in the complex neuronal networks in which memories are formed and stored. Genetic engineering strategies were used to increase or decrease the expression of Fyn, which regulates many other proteins through the attachment of specific groups of atoms known as phosphate groups.

The researchers determined that changing levels of Fyn had no effect on plaque formation or aberrant sprouting (the abnormal growth of nerve terminals, in which neuchemical messages are stored), indicating that these pathologies involve discrete molecular mechanisms. However, they observed that blocking Fyn expression prevented amyloid proteins from damaging synapses, the specialized connections between brain cells, and improved the longevity of mice. (Experimental mice with Alzheimer's-like disease otherwise die prematurely.) In contrast, increasing Fyn in the brain worsened synaptic damage, and also increased the number of premature deaths in the mice.

Loss of synapses and abnormal outgrowth of nerve terminals occur both in people with Alzheimer's disease and in transgenic mice producing human amyloid proteins in the brain (the model used in the study). Humans with the disease, like mice, die prematurely.

"Synaptic degeneration in Alzheimer's disease is like electrical circuits in a computer becoming faulty -- signals can no longer be transmitted through broken connections," says senior author and GIND director Lennart Mucke, MD, who
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-476-2557
University of California - San Francisco
19-May-2004


Page: 1 2

Related medicine news :

1. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
2. Neuronal death and processing of Tau protein in Alzheimers disease
3. Researchers discover link between insulin and Alzheimers
4. New trials for counseling caregivers and patients with Alzheimers begin
5. Marijuana ingredient may stall decline from Alzheimers
6. Drugs used to treat Alzheimers in nursing homes are worsening sufferers illness
7. UT Southwestern doctors track Oklahoma Alzheimers patients via telemedicine
8. Contrary to previous findings, smoking is detrimental to patients with Alzheimers
9. Nanoscale diagnostic sets sights on Alzheimers
10. New test is first step in early detection of Alzheimers disease
11. Older people with the Alzheimers gene find it harder to remember to remember even if healthy

Post Your Comments:
(Date:9/1/2015)... ... September 01, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... for Lymphoma awareness initiative, the nation’s premier and most high-profile lymphoma awareness campaign. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. ... issues and needs. Money for Good 2015, released today by Camber Collective, goes to ... annual potential to mobilize up to $22B in new philanthropic giving and shift $25B ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers ... American Society for Dermatologic Surgery, according to a new survey that also offers ... on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ...
(Date:9/1/2015)... Fairfax, VA (PRWEB) , ... September 01, 2015 ... ... the Mane Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s ... modern technology, and beauty tools. In her upcoming city-to-city tour, Ellis will be ...
(Date:9/1/2015)... ... ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation Hospital ... Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the Friends ... to support patients and their families during their time at Magee Rehabilitation Hospital. ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3
(Date:9/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... the Patent Trial and Appeals Board (PTAB) in response ... filed by a unit of Boston Scientific Corporation, challenging ... 8,359,102 (the ,102 patent). The ,102 patent is one of Nevro,s 55 ...
(Date:9/1/2015)... , Sept. 1, 2015 Ardelyx, ... company focused on gastrointestinal and cardio-renal diseases, today ... of the option and license agreement for Ardelyx,s ... There was no payment associated with termination and ... 2014, Ardelyx and Sanofi entered into an option ...
(Date:9/1/2015)... 1, 2015 NOWDiagnostics Inc., based in Springdale, ... of Canada , a move that ... world where people have greater access to information concerning ... line of unique blood-based rapid tests that allow health ... a variety of ailments and diseases. ZBx Corporation, a ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3
Cached News: